Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have
substantially improved anticoagulation therapy for prevention of stroke and systemic …

Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …

Aims Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …

Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for
stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in …

Aims Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from
cardiovascular complications including cardiovascular death, stroke, and major bleeding. To …

Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in
numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from …

Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …

Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …

Abstract Background Direct oral anticoagulants (DOACs) are the recommended first‐line
therapy for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) …

Aims Non-vitamin K antagonist oral anticoagulants represent a new option for prevention of
embolic events in patients with atrial fibrillation (AF). However, little is known about the …